Inventaire - your friends and communities are your best library

First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study

এতে প্রকাশিত: Annals of Oncology

তারিখে প্রকাশিত: 2015-06-23

মূল বিষয়: রোগী, ফুসফুসের ক্যান্সার

Cites articles 18

তারিখ

শিরোনাম

লেখকগণ

2015-02

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

Vera Gorbunova, Sergey Orlov, James Chih-Hsin Yang, সঞ্জয় পোপাট, Michael J. Boyer, Wu-Chou Su, Tony Mok, Lecia V Sequist
2014-12-15

Efficacy of EGFR tyrosine kinase inhibitors in non-small-cell lung cancer patients with/without EGFR-mutation: evidence based on recent phase III randomized trials
2014-02-03

The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial

Enriqueta Felip, Rafael Rosell, Trever G Bivona, Enric Carcereny, Radj Gervais, Bartomeu Massuti, Teresa Morán-López, Rosario Garcia-Campelo, Ana Drozdowskyj, Miguel Ángel Molina-Gutiérrez, Miquel Taron, Niki Karachaliou, Ana Giménez-Capitán, Margarita Majem Tarruella, Santiago Viteri
2014-02

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial

Yi-Long Wu
2013-01

Cancer statistics, 2013
2013-04-01

EGFR through STAT3 modulates ΔN63α expression to sustain tumor-initiating cell proliferation in squamous cell carcinomas

Sonia Fabris, Elda Tagliabue, Antonino Neri, Andrea Balsari
2013-07-31

A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC).
2013-07-01

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations

James Chih-Hsin Yang, Tony Mok, Sergey Orlov, Michael J. Boyer, Wu-Chou Su, Lecia V Sequist
2012-03

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rafael Rosell, Angel Artal, Mariano Provencio, Vittorio Gebbia, Alessandra Bearz, Giuseppe Altavilla, Julien Mazieres, Pilar Garrido, Enriqueta Felip, Alain Vergnenegre, Flavia Longo, Enric Carcereny, Radj Gervais, Bartomeu Massuti, Ramon Palmero, Antonio Ramón Gómez-García, Rut Porta, Teresa Morán-López, Amelia Insa, Filippo de Marinis, Romain Corre, Isabel Bover, Noemi Reguart, Dolores Isla, Rosario Garcia-Campelo, Maria Sanchez-Ronco, Ana Drozdowskyj, Cristina Queralt, Itziar de Aguirre, Miguel Ángel Molina-Gutiérrez, Miquel Taron
2011-07-23

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Yi-Long Wu
2010-06-24

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR
2009-08-19

Screening for epidermal growth factor receptor mutations in lung cancer

Carlos Camps, Mariano Provencio, Christian Rolfo
2009-08-19

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Tony Mok, Yi-Long Wu
2008-04-14

Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals
2007-05-01

Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China

Yi-Long Wu, Tony Mok
2006-07-01

Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib

Matthew Meyerson, Pasi A Jänne, Daniel Haber, Lecia V Sequist
2005-03-02

Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers
2005-07-14

Erlotinib in previously treated non-small-cell lung cancer

নিবন্ধ - wd:Q38536391

জায়ে আপনাকে স্বাগত

the library of your friends and communities

আরো জানুন